Bosun Asset Management LLC Trims Stake in Twist Bioscience Co. (NASDAQ:TWST)

Bosun Asset Management LLC cut its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 49.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,091 shares of the company's stock after selling 7,876 shares during the quarter. Bosun Asset Management LLC's holdings in Twist Bioscience were worth $376,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after purchasing an additional 189,791 shares during the period. ARK Investment Management LLC raised its position in Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after buying an additional 237,772 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after acquiring an additional 532,040 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Twist Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock worth $63,895,000 after purchasing an additional 6,908 shares during the last quarter. Finally, First Light Asset Management LLC purchased a new stake in Twist Bioscience in the 4th quarter valued at about $56,984,000.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $1.52 during mid-day trading on Monday, reaching $32.34. 290,791 shares of the company traded hands, compared to its average volume of 1,085,006. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 52 week low of $30.72 and a 52 week high of $60.90. The firm has a market cap of $1.94 billion, a PE ratio of -9.55 and a beta of 2.54. The company's 50 day moving average price is $38.63 and its 200-day moving average price is $43.69.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. On average, equities analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TWST shares. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group lowered their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Guggenheim reissued a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Robert W. Baird cut their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Twist Bioscience has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Insider Activity

In other news, insider Dennis Cho sold 689 shares of Twist Bioscience stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $25,940.85. Following the completion of the sale, the insider now directly owns 110,849 shares in the company, valued at approximately $4,173,464.85. This trade represents a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,726 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the sale, the chief executive officer now directly owns 660,966 shares of the company's stock, valued at $27,549,062.88. This represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,991 shares of company stock valued at $742,654. 3.01% of the stock is currently owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.